VidaVinci, Inc.
Morvarid (Mori) Mohseni currently serves as the Vice President and Head of Biology at VidaVinci, Inc. since June 2025. Mori has held significant positions in the biotechnology and pharmaceutical sectors, including Executive Director of Biological Sciences at Kymera Therapeutics from October 2023 to June 2025, and Director of Oncology Drug Discovery at Bristol Myers Squibb from May 2020 to October 2023. Previous roles at Bristol included Associate Director of Oncology Discovery Pharmacology and In vivo Biology. At Novartis Institutes for BioMedical Research, Mori advanced through various roles, culminating as Senior Principal Scientist in Oncology Drug Discovery. Early career experience includes a position as Senior Scientist at AstraZeneca. Mori holds a Ph.D. in Pharmacology from the University of Illinois College of Medicine and completed a fellowship at Harvard University in Hematology/Oncology and Stem Cell & Regenerative Biology.
This person is not in any teams
This person is not in any offices
VidaVinci, Inc.
VidaVinci, Inc is a venture-backed, privately held biotech company on a mission to pioneer "a new modality to end all modalities". Our goal is to revolutionize drug discovery at scale, address the toughest challenges of existing modalities, and unlock high-impact therapies for patients. Backed by top tier investors, the Company is co-founded by Drs. Gregory Verdine and Hal Barron--renowned industry leaders known for taking on the most daring scientific challenges. Built on a bold vision to redefine therapeutic innovation, we are pushing the boundaries of what’s possible in medicine. Join us to shape the future of drug discovery.